Results 141 to 150 of about 7,354 (172)

Impacts and New Challenges with Highly Effective Modulator Therapies in Younger Children with Cystic Fibrosis. [PDF]

J Clin Med
Uyangoda K, Dawson C, Gudka N, Brugha R.
europepmc   +1 more source

Effect of elexacaftor/tezacaftor/ivacaftor on systemic inflammation in cystic fibrosis. [PDF]

Thorax
Maher RE, Cytlak-Chaudhuri UM, Aleem S, Barry P, Brice DP, Caamaño Gutiérrez E, Driver K, Emmott E, Rothwell A, Smith E, Travis M, Lee D, McNamara PS, Waller I, Smith JA, Jones A, Lord RW.   +16 more
europepmc   +1 more source

Nutritional outcomes in people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor: A 24-mo real-world study

Gianfranco Alicandro, Laura Zazzeron, Valentina Visciola, Anna Bulfamante, Arianna Biffi, Fabiola Corti, Andrea Gramegna, Francesco Blasi, Valeria Daccò   +8 more
openalex   +1 more source

Efficacy and safety of using Elexacaftor/Tezacaftor/Ivacaftor in the treatment of children with cystic fibrosis: real-world evidence from Brazil. [PDF]

J Pediatr (Rio J)
Martins GDS, Rambo C, Spessatto G, Saab MM, João BHD, Fajardo AD, Primon JG, Picciani TG, da Cunha RC, Chong-Neto HJ, Massignan CRL, Silva-Filho LVRFD, Riedi CA, Filho NAR, Chong-Silva DC.   +14 more
europepmc   +1 more source

Ivacaftor-tezacaftor-elexacaftor, tezacaftor-ivacaftor and lumacaftor-ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation.

Health Technol Assess
Edwards SJ, Farrar BG, Ennis K, Downes N, Wakefield V, Mackenzie I, Walters A, Jhita T.   +7 more
europepmc   +1 more source

Cystic fibrosis liver disease progression in the era of elexacaftor-tezacaftor-ivacaftor. [PDF]

JHEP Rep
Mouliade C, Parlati L, Tzedakis S, Collier M, Bouam S, Vallet-Pichard A, D'Halluin-Venier V, Kanaan R, Pol S, Sogni P, Burgel PR, Mallet V, Demosthenes Research Group.   +12 more
europepmc   +1 more source

The effect of elexacaftor-tezacaftor-ivacaftor on liver stiffness in children with cystic fibrosis. [PDF]

J Pediatr Gastroenterol Nutr
Diemer S, Elidottir H, Eklund EA, Påhlman LI, Hansen C.   +4 more
europepmc   +1 more source

Acute cholecystitis as an adverse effect of treatment with elexacaftor/tezacaftor/ivacaftor in a patient with cystic fibrosis

Carlos Martín de Vicente, Silvia Jade Cáceres Barrera, Sánchez González, Cristina Alonso, Ruth García Romero   +4 more
openalex   +1 more source

Corrigendum: Inhibitory effects of calcium channel blockers nisoldipine and nimodipine on ivacaftor metabolism and their underlying mechanism

Frontiers in Pharmacology
Hailun Xia, Xinhao Xu, Jie Chen, Hualu Wu, Yuxin Shen, Xiaohai Chen, Ren-ai Xu, Wenzhi Wu   +7 more
doaj   +1 more source

Hemoglobin Levels in Children Treated for Cystic Fibrosis with CFTR Modulators: A Single Center Retrospective Study. [PDF]

J Clin Med
Tosco A, Cerchione R, Gelzo M, Cimbalo C, Castaldo A, Terracciano R, Raia V, Sepe A.   +7 more
europepmc   +1 more source